Categories
BLOG

cbd project

Project CBD Sunday: What Is CBD?

Copy this post to your clipboard

Thanks to our friends at Project CBD for allowing us to re-post this article.

INTRO TO CBD

Cannabidiol ( CBD ) is a naturally occurring compound found in the resinous flower of cannabis, a plant with a rich history as a medicine going back thousands of years. Today the therapeutic properties of CBD are being tested and confirmed by scientists and doctors around the world. A safe, non-addictive substance, CBD is one of more than a hundred “phytocannabinoids,” which are unique to cannabis and endow the plant with its robust therapeutic profile.

CBD is closely related to another important medicinally active phytocannabinoid: tetrahydrocannabinol ( THC ), the compound that causes the high that cannabis is famous for. These are the two components of cannabis that have been most studied by scientists.

The fact that CBD is therapeutically potent as well as non-intoxicating, and easy to take as a CBD oil, makes it an appealing treatment option for those who are cautious about trying cannabis for the first time.

Both CBD and THC have significant therapeutic attributes. But unlike THC , CBD does not make a person feel “stoned” or intoxicated. That’s because CBD and THC act in different ways on different receptors in the brain and body.

CBD can actually lessen or neutralize the psychoactive effects of THC , depending on how much of each compound is consumed. Many people want the health benefits of cannabis without the high – or with less of a high.

The fact that CBD is therapeutically potent as well as non-intoxicating, and easy to take as a CBD oil, makes it an appealing treatment option for those who are cautious about trying cannabis for the first time.

CBD : THE MULTIPURPOSE MOLECULE

Many people are seeking alternatives to pharmaceuticals with harsh side effects – medicine more in synch with natural processes. By tapping into how we function biologically on a deep level, CBD can provide relief for chronic pain, anxiety, inflammation, depression and many other conditions.

CBD has proven neuroprotective effects and its anti-cancer properties are being investigated at several academic research centers in the United States and elsewhere.

Extensive scientific research – much of it sponsored by the U.S. government – and mounting anecdotal accounts from patients and physicians highlight CBD ’s potential as a treatment for a wide range of maladies, including (but not limited to):

  • Autoimmune diseases (inflammation, rheumatoid arthritis)
  • Neurological conditions (Alzheimer’s, dementia, Parkinson’s, multiple sclerosis, epilepsy, Huntington’s chorea, stroke, traumatic brain injury)
  • Metabolic syndrome (diabetes, obesity)
  • Neuropsychiatric illness (autism, ADHD , PTSD , alcoholism)
  • Gut disorders (colitis, Crohn’s)
  • Cardiovascular dysfunction (atherosclerosis, arrhythmia)
  • Skin disease (acne, dermatitis, psoriasis)

CBD has proven neuroprotective effects and its anti-cancer properties are being investigated at several academic research centers in the United States and elsewhere. A 2010 brain cancer study by California scientists found that CBD “enhances the inhibitory effects of THC on human glioblastoma cell proliferation and survival.” This means that CBD makes THC even more potent as an anticancer substance. Also in 2010, German researchers reported that CBD stimulates neurogenesis, the growth of new brain cells, in adult mammals.

HOW DOES CBD WORK?

CBD and THC interact with our bodies in a variety of ways. One of the main ways they impact us is by mimicking and augmenting the effects of the compounds in our bodies called “endogenous cannabinoids” – so named because of their similarity to the compounds found in the cannabis plant. These “endocannabinoids” are part of a regulatory system called the “endocannabinoid system”.

The discovery of the endocannabinoid system has significantly advanced our understanding of health and disease. It has major implications for nearly every area of medical science and helps to explain how and why CBD and THC are such versatile compounds – and why cannabis is such a widely consumed mood-altering plant, despite its illegal status.

The endocannabinoid system plays a crucial role in regulating a broad range of physiological processes that affect our everyday experience – our mood, our energy level, our intestinal fortitude, immune activity, blood pressure, bone density, glucose metabolism, how we experience pain, stress, hunger, and more.

What happens if the endocannabinoid system doesn’t function properly? What are the consequences of a chronically deficient or overactive endocannabinoid system?

In a word, disease.

By modulating the endocannabinoid system and enhancing endocannabinoid tone, CBD and THC can slow – or in some cases stop – disease progression.

Cutting-edge science has shown that the endocannabinoid system is dysregulated in nearly all pathological conditions. Thus, it stands to reason that “modulating endocannabinoid system activity may have therapeutic potential in almost all diseases affecting humans,” as Pal Pacher and George Kunos, scientists with the U.S. National Institutes of Health ( NIH ), suggested in a 2014 publication.

By modulating the endocannabinoid system and enhancing endocannabinoid tone, CBD and THC can slow – or in some cases stop – disease progression.

PHARMACEUTICAL CBD

There’s a lot of excitement about the healing potential of CBD – with good reason.

But it wasn’t until June 25, 2018, that the U.S. Food and Drug Administration ( FDA ) recognized cannabidiol as a real medicine by approving Epidiolex, an almost pure pharmaceutical CBD formulation, as a treatment for two severe pediatric seizure disorders, Lennox-Gastaut syndrome and Dravet syndrome.

This was the first time since the peak of the reefer madness era 80 years ago – when “marihuana” became a crime instead of a cure — that the federal government had given an official thumbs-up for a cannabis-derived product.

In response to the FDA ’s historic decision, the Drug Enforcement Administration ( DEA ) announced in September 2018 that it had removed Epidiolex from Schedule I classification, a category reserved for dangerous drugs with no medical value. Henceforth, Epidiolex would be considered a Schedule V drug, the least dangerous designation under the Controlled Substances Act.

But the DEA kept cannabis and CBD itself on Schedule I as an illegal narcotic. In the world according to Uncle Sam, pharmaceutical CBD is officially the only good cannabinoid while the rest of the plant remains an ‘evil’ weed.

Given CBD ’s reputation as a popular, artisanal remedy, one would think that Epidiolex would command a lot of “off label” attention. After all, physicians often prescribe pharmaceuticals off label to treat conditions that were not the actual focus of clinical trials. But the costly price tag for Epidiolex (more than $30,000 annually) precludes off label prescribing as well as affordable access for tens of millions of Americans without health insurance.

CBD OIL

For those who can’t obtain pharmaceutical CBD , there are numerous internet storefronts, community markets, coffee shops, health clubs, chiropractic offices, upscale boutiques and gas stations that retail various hemp-derived CBD oil products, including pure CBD isolates comparable in chemical make-up to Epidiolex.

CBD oil products and flower with varying levels of THC and CBD are also available for smoking or vaping at cannabis dispensaries in states that have legalized the herb for therapeutic use.

CBD oil has been touted as a curative for the sick and a preventive for the healthy, an all-purpose palliative for pets as well as people of all ages.

In response to massive consumer demand, a huge, unregulated market in CBD oil products reached a critical mass in 2018. A surge of consumer interest in all things CBD was suddenly newsworthy with hosanas of praise coming from athletes, film stars, soccer moms, and parents of desperately ill children.

CBD oil has been touted as a curative for the sick and a preventive for the healthy, an all-purpose palliative for pets as well as people of all ages.

But along with a growing awareness of cannabidiol as a potential health aide, there has also been a proliferation of misconceptions about CBD and cannabis therapeutics.

THE CBD CHALLENGE

CBD is a molecule, not a miracle. Many people could benefit significantly from legal access to a wide range of cannabis remedies, not just low- THC or no- THC products. CBD alone may not always do the trick. There is compelling evidence that CBD works best in combination with THC and the full spectrum of other cannabis components.

Figuring out how to optimize one’s therapeutic use of cannabis is the driving force behind the great laboratory experiment in democracy known as medical marijuana that’s been unfolding state-by-state and country-by-country in recent years.

The advent of potent cannabis oil concentrates, non-intoxicating CBD -rich products, and innovative, smokeless delivery systems has transformed the therapeutic landscape and changed the public conversation about cannabis.

Most health professionals know little about CBD or cannabis therapeutics and they lack sufficient expertise to adequately counsel patients regarding dosage, modes of administration, CBD / THC synergies, and any risk factors, including interactions with other drugs.

It’s no longer a matter of debating whether cannabis has merit as an herbal medication – today the key challenge is discerning how to utilize cannabis for maximum therapeutic benefit. Given its low-risk profile, many people are using CBD as an add-on therapy to their existing treatment plans.

But most health professionals know little about CBD or cannabis therapeutics and they lack sufficient expertise to adequately counsel patients regarding dosage, modes of administration, CBD / THC synergies, and any risk factors, including interactions with other drugs.

Instead, the onus has been on a loose-knit community of self-reliant patients, supportive families and a few pioneer physicians who’ve learned a lot through trial and error and shared information about how to navigate promising avenues of cannabis therapy.

WHAT ABOUT CBD FROM HEMP?

What began as a grassroots populist rebellion against cannabis prohibition would morph into a multibillion-dollar market catalyzed by the rediscovery of CBD as a wellness option. CBD oil is red hot and it seems that everyone – do-gooders as well as profiteers – wants a piece of the action.

CBD has also catalyzed the rebirth of the U.S. hemp industry, which lay dormant for decades because of drug war politics. The 2018 Farm Bill includes a provision that legalizes the cultivation of hemp (cannabis with less than 0.3 percent THC ) in large part because of the popularity and driving economic force of CBD .

Growing hemp is now a legitimate agricultural enterprise in the United States. But extracting CBD -rich oil from hemp biomass and marketing CBD oil concentrates and isolates for ingestion and inhalation steps on Big Pharma’s toes and is frowned upon by the DEA and the FDA .

The upside of all this is easy access to CBD oil; the downside is inconsistent quality.

Legalities aside, hemp-derived cannabidiol is just a mouse click or a phone tap away for anyone willing to roll the dice and purchase CBD oil products that are manufactured with little regulatory oversight.

The upside of all this is easy access to CBD oil; the downside is inconsistent quality.

Many hemp-derived CBD oil products are mislabeled as to cannabidiol and THC content. And poorly processed CBD oil may be tainted with toxic solvent residues, pesticides, corn syrup, artificial flavors and colors, and other contaminants.

Fortunately, good quality CBD oil products are also available for the conscientious consumer – the label reader, the brand researcher – who understands that cannabis and CBD are best used as part of a healthy lifestyle.

Copyright, Project CBD . May not be reprinted without permission.

Thanks to our friends at Project CBD for allowing us to re-post this article. INTRO TO CBD Cannabidiol (CBD) is a naturally occurring compound found in the

CBD Research Project

After William’s tumour reduction, a team at one of the world leading research centres into William’s type of tumour, the Children’s Brain Tumour Research Centre, agreed to write a research proposal into Cannabidiol and it’s effect on Ependymoma

After a period of campaigning, individual donations and two significant contributions from Astro Brain Tumour Fund and Brain Tumour Action , the £100,000 target required for the project to go ahead was reached

Our hopes for the research are that:

  • We’ll find out if it’s the drug that reduced William’s tumour
  • We’ll find out what the optimum dosage is
  • We’ll have a better chance of having the drug funded by the NHS
  • Other children and their families can benefit
  • This could be a game changer for other types of cancer

Research Proposal Lay Summary

In vitro evaluation of the effect of cannabidiol as an adjuvant therapy for paediatric brain tumours

Dr Lisa Storer, Associate Professor Saoirse O’Sullivan and Professor Richard Grundy

“Brain tumours are the leading cause of cancer related death in children and are one of the most challenging childhood cancers to diagnose and to treat. Only 50-60-% of children diagnosed with a brain tumour are cured and 60% of those cured are left with a disability affecting quality of survival. Ependymoma and high grade glioma account for up to a quarter of all children diagnosed with a brain tumour. Compared to other childhood brain tumours 5-year survival rates are relatively poor. It has been reported that 39-64% of those diagnosed with an ependymoma will still be alive 5 years after diagnosis and that 15-35% of those diagnosed with a high grade glioma will survive this length of time. In addition, tumour recurrences are common with treatment options becoming more limited and many children dying from the disease. We therefore would like to investigate other treatment options which could be used in conjunction with standard therapies.

Cannabidiol (CBD) is one of the active cannabinoids found in the Cannabis plant. It has been shown to have a lack of side effects, including a lack of psychoactive side effects which are more commonly experienced with other active agents found in cannabis. It has also been shown not to interfere with several psychomotor and psychological functions and therefore it is under consideration for a wide range of potential medical applications. CBD is already in use in childhood epilepsy patients so it has already been subject to rigorous testing, clinical trials and safety examinations and there are currently a number of clinical trials in progress to obtain safety and efficacy data on CBD in other conditions including Dravet syndrome and Tuberous Sclerosis Complex. This means that it could quickly be re-purposed as an anti-cancer drug.

We are therefore interested in investigating whether CBD can be used as a way of attacking cancer cells. In order to do this we would like to grow brain tumour cells and normal brain cells in the presence of CBD. The brain tumour cells we will use have all been grown from either Ependymoma or high grade glioma tumours. We will grow them under standard conditions in the presence and absence of CBD. After 7 days we will measure the level of cell death and how many viable cells are present by two different assays. We will then perform different stains on the cells to see how many of the cells are dividing, whether the cells are undergoing cell death and also for a group of proteins which regulate the expression of genes [peroxisome proliferator-activated receptors (PPARs)]. These PPARs play essential roles in the regulation of cell differentiation, development, metabolism and the formation of cancer. We expect the cells (brain tumour and normal brain) grown in our standard conditions to be healthy and actively dividing. We expect that normal brain cells grown in CBD to also be healthy. However, we expect the brain tumour cells grown in CBD to be unhealthy and dying.

The James Lind Alliance priority setting partnerships were created in 2015 to identify clinical research questions of greatest importance to the patients and families actually affected by brain tumours. One of the questions raised was “How effective are complementary and alternative medicines, which include supplements and herbal remedies, compared to standard treatment alone, for extending and improving quality of life in malignant brain tumour patients?” We would include the use of CBD in this category and therefore feel that it is timely to perform this research which will give us vital information into the potential clinical effectiveness of CBD in paediatric brain tumours.”

After William's tumour reduction, a team at one of the world leading research centres into William's type of tumour, the Children's Brain Tumour Research Centre, agreed to write a research proposal into Cannabidiol and it's effect on Ependymoma After a period of campaigning, individual donations and two significant contributions from Astro Brain Tumour Fund and…